Transcranial Focused Ultrasound Attenuates Post-Stroke Neuroinflammation via the Nespas/miR-383-3p/SHP2 Pathway

Study Background and Research Question

Acute ischemic stroke remains a leading cause of morbidity and mortality worldwide, with limited therapeutic options primarily due to the narrow window for thrombolysis and post-injury complications. Neuroinflammation, particularly mediated by microglial activation and the NLRP3 inflammasome, is a critical determinant of secondary injury and functional outcome after stroke. Noninvasive neuromodulation approaches, such as transcranial focused ultrasound stimulation (tFUS), have shown promise in mitigating neuroinflammation, but their precise molecular mechanisms have not been fully elucidated. This study sought to clarify how tFUS modulates neuroinflammatory signaling following ischemic insult, focusing on the Nespas/miR-383-3p/SHP2 regulatory axis (paper).

Key Innovation from the Reference Study

The central innovation lies in identifying the Nespas/miR-383-3p/SHP2 signaling pathway as a pivotal mediator of tFUS-induced neuroprotection. While previous research established that tFUS can reduce infarct volume and improve neurological function post-stroke, this paper provides direct evidence that tFUS upregulates Nespas, a long noncoding RNA, which in turn modulates miR-383-3p and ultimately increases SHP2 (Src homology 2 domain-containing phosphatase 2) activity. Notably, this axis suppresses NLRP3 inflammasome activation in microglia, thus attenuating neuroinflammation (paper). The study delineates a previously uncharacterized mechanism, positioning SHP2 as a targetable node in post-stroke inflammatory signaling.

Methods and Experimental Design Insights

The authors employed a well-validated transient middle cerebral artery occlusion (MCAO) model in rats to mimic ischemic stroke. Low-intensity tFUS was administered to the ischemic hemisphere 24 hours post-occlusion, continuing for seven days. Neurobehavioral assessments, infarct volume quantification, and immunohistochemical analyses were performed to evaluate neurological outcomes and neuroinflammation. Molecular mechanisms were dissected using Western blotting, quantitative RT-PCR, immunofluorescence, and RNA sequencing. In vitro, BV2 microglia subjected to oxygen-glucose deprivation/reperfusion (OGD/R) allowed mechanistic exploration of the Nespas/miR-383-3p/SHP2 axis. Additional experiments involved Nespas silencing and SHP2 inhibition to assess pathway specificity (paper).

Core Findings and Why They Matter

The study established several key findings:

• tFUS improves neurological function and reduces infarct size: Behavioral testing and infarct quantification revealed significant neuroprotection with tFUS treatment compared to controls (paper).
• Suppression of NLRP3 inflammasome activation: tFUS-treated animals exhibited decreased expression of NLRP3 and associated pro-inflammatory cytokines, implicating effective attenuation of microglia-driven neuroinflammation.
• Upregulation of Nespas and SHP2: tFUS increased Nespas expression, which positively regulated SHP2 levels via miR-383-3p modulation. Silencing Nespas or inhibiting SHP2 reversed the anti-inflammatory effects, confirming the pathway's functional importance.
• Mechanistic specificity: In vitro studies demonstrated that modulation of Nespas or SHP2 directly affected NLRP3 activation in microglia, supporting a direct mechanistic link.

These findings collectively position the Nespas/miR-383-3p/SHP2 axis as a critical effector of tFUS-mediated neuroprotection. The implication is twofold: tFUS offers a noninvasive modality to target detrimental neuroinflammation, and SHP2 emerges as a potential molecular target for stroke intervention.

Comparison with Existing Internal Articles

Recent internal reviews, such as "NSC 87877: Reliable Shp2 Inhibition for Cell-Based Assays" and "Strategic Targeting of Shp2: Translational Leverage with NSC 87877," have highlighted the utility of selective Shp2 inhibitors in dissecting phosphatase-dependent signaling in oncology and neuroinflammation models (internal article; internal article). The present study adds critical in vivo evidence to this mechanistic context by showing that SHP2 is not only a signaling intermediary in cell-based models but also a decisive regulator of neuroinflammatory responses after ischemic stroke. The axis described (Nespas/miR-383-3p/SHP2) provides a mechanistic bridge between the molecular pharmacology of SHP2 and translational neuroprotection, as further discussed in "NSC 87877: Shp2 Inhibition and the Future of Neuroinflammation Research" (internal article). By mechanistically validating SHP2 as a modulator of post-stroke inflammation, the current paper substantiates previous recommendations to employ selective SHP2 inhibitors, such as NSC 87877, in preclinical neuroinflammation workflows.

Limitations and Transferability

While the study provides compelling evidence in a rat MCAO model, several limitations exist. The use of a single animal model and cell line (BV2 microglia) may not fully recapitulate the complexity of human neuroinflammatory responses. The tFUS parameters optimized for rodents may require further validation and calibration for clinical translation. Additionally, while the Nespas/miR-383-3p/SHP2 pathway was shown to be necessary for tFUS-mediated neuroprotection, the broader network of post-ischemic signaling—such as interactions with other phosphatases or cytokines—was not explored in detail (paper). These findings are most directly transferable to experimental models focused on neuroinflammation, and additional studies are warranted to assess relevance in other contexts, such as chronic neurodegeneration or peripheral inflammation.

Protocol Parameters

• tFUS (in vivo rat MCAO) | Low-intensity, daily ×7 days post-stroke | Acute ischemic stroke neuroprotection | Matches clinical-relevant window for neuroprotective intervention | paper
• SHP2 inhibition (pharmacological, in vitro) | Use of selective Shp2 inhibitor (e.g., 0.3–1 μM for NSC 87877) | Microglial NLRP3 pathway investigation | Reflects dose ranges with demonstrated selectivity and cytotoxicity in cell models | product_spec, workflow_recommendation
• Nespas silencing (cell transfection) | siRNA-mediated knockdown | Pathway validation in microglia | Confirmed necessity for tFUS-induced anti-inflammatory effects | paper

Research Support Resources

For researchers aiming to dissect SHP2-dependent signaling in neuroinflammation or ischemic injury models, selective chemical tools are essential. NSC 87877 (SKU A4544) is a potent and selective Shp2 inhibitor with demonstrated utility in cell-based and in vivo studies investigating SHP2’s role in cytokine signaling, NLRP3 activation, and neuroinflammatory responses (source: product_spec; internal article). Its selectivity profile and established use in similar assay systems make it suitable for validating SHP2 function in experimental workflows modeled on the reference study. For further protocol guidance and mechanistic discussion, see the internal reviews linked above.